Blood biomarkers are measurable substances in blood that reflect physiological or pathological processes and are increasingly used to detect and monitor neurological and psychiatric conditions. Recent research focuses on proteins, lipids, metabolites and inflammatory markers that can indicate brain changes long before symptoms are obvious.

In Alzheimer’s disease, key biomarkers include amyloid beta peptides and phosphorylated tau. Abnormal levels of these proteins in blood parallel pathological changes in the brain, offering a less invasive alternative to cerebrospinal fluid analysis or imaging. Studies show that specific forms of phosphorylated tau can distinguish Alzheimer’s from other dementias and predict progression from mild cognitive impairment.

Inflammatory biomarkers such as cytokines and C reactive protein provide insight into neuroinflammation, which appears central to many brain disorders. Altered inflammatory profiles are reported in depression, schizophrenia and neurodegenerative diseases, suggesting a link between peripheral immune activation and central nervous system dysfunction.

Metabolic and oxidative stress markers, including homocysteine and various lipid species, are associated with cognitive decline and vascular contributions to dementia. Changes in lipid metabolism may help differentiate dementia subtypes and track disease course.

In psychiatry, panels of blood markers are being explored to support diagnosis, stratify patients and predict treatment response. Combinations of inflammatory, hormonal and metabolic indicators show promise for characterizing subgroups within disorders like major depression.

Overall, research indicates that multiplex panels of blood biomarkers, interpreted with clinical and imaging data, could transform early detection, prognosis and personalized treatment in brain and mental health disorders, though large validation studies and standardization are still needed.